BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis (vol 13, 838449, 2022)

被引：3

作者：

Herrmann, Franziska Elena ^{[1
]}

Hesslinger, Christian ^{[1
]}

Wollin, Lutz ^{[1
]}

Nickolaus, Peter ^{[1
]}

机构：

[1] Boehringer Ingelheim Pharm GmbH & Co KG, Biberach An Der Riss, Germany

来源：

FRONTIERS IN PHARMACOLOGY | 2023年 / 14卷

关键词：

PDE4B; IPF; lung fibrosis; phosphodiesterase; cAMP; ILDs;

D O I：

10.3389/fphar.2023.1219760

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页数：2

共 19 条

[11] Safety and Efficacy of BI 1015550, a Preferential Inhibitor of Phosphodiesterase 4B, in Patients with Idiopathic Pulmonary Fibrosis: a Phase 2 Trial*
Koschel, Autoren D.
Richeldi, L.
Azuma, A.
Cottin, V
Hesslinger, C.
Stowasser, S.
Valenzuela, C.
Wijsenbeek, M.
Zoz, D.
Voss, F.
Maher, T.
PNEUMOLOGIE, 2023, 77 : S51 - S52
[12] Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Maher, Toby M.
Schlecker, Christina
Luedtke, Doreen
Bossert, Sebastian
Zoz, Donald F.
Schultz, Armin
ERJ OPEN RESEARCH, 2022, 8 (04)
[13] PDE4B inhibitor BI1015550 improves lung fibrosis, modulates transcriptome in bleomycin-treated rats, and attenuates fibrotic markers in human lung fibroblasts and epithelial cells
Reininger, Dennis
Herrmann, Franziska Elena
Nickolaus, Peter
Wollin, Lutz
Laemmle, Baerbel
Quast, Karsten
Fundel-Clemens, Katrin
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[14] Phosphodiesterase 4B Inhibitor for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Gillissen, A.
ZEITSCHRIFT FUR PNEUMOLOGIE, 2022, 19 (06): : 387 - 388
[15] Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry
Cuozzo, John W.
Clark, Matthew A.
Keefe, Anthony D.
Kohlmann, Anna
Mulvihill, Mark
Ni, Haihong
Renzetti, Louis M.
Resnicow, Daniel, I
Ruebsam, Frank
Sigel, Eric A.
Thomson, Heather A.
Wang, Ce
Xie, Zhifeng
Zhang, Ying
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (14) : 7840 - 7856
[16] Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-b1 pathway (vol 157, pg 229, 2018)
Li, Xiaohe
Lu, Cheng
Liu, Shuangwei
Liu, Shuaishuai
Su, Chengcheng
Xiao, Ting
Bi, Zhun
Sheng, Pengzhen
Huang, Mengying
Liu, Xinhua
Wei, Yujiao
Zhao, Lin
Miao, Shengxiang
Mao, Jiahe
Huang, Kai
Gao, Shaoyan
Liu, Ning
Qi, Min
Liu, Tongtong
Qin, Shuanglin
Wei, Luqing
Sun, Tao
Ning, Wen
Yang, Guang
Zhou, Honggang
Yang, Cheng
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 163 : 403 - 403
[17] Phosphodiesterase-4B-Inhibitor zur Behandlung der idiopathischen Lungenfibrose (IPF)Phosphodiesterase 4B inhibitor for the treatment of idiopathic pulmonary fibrosis
A. Gillissen
Zeitschrift für Pneumologie, 2022, 19 (6) : 387 - 388
[18] CKD-506, a Selective HDAC6 Inhibitor, Is a First-in-Class Drug Candidate for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Lee, S.
Kim, M.
Baek, J.
Suh, D.
Song, J.
Ha, N.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
[19] Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis
Desroy, Nicolas
Housseman, Christopher
Bock, Xavier
Joncour, Agnes
Bienvenu, Natacha
Cherel, Laetitia
Labeguere, Virginie
Rondet, Emilie
Peixoto, Christophe
Grassot, Jean-Marie
Picolet, Olivier
Annoott, Denis
Triballeau, Nicolas
Monjardet, Alain
Wakselman, Emanuelle
Roncoroni, Veronique
Le Tallec, Sandrine
Blanque, Roland
Cottereaux, Celine
Vandervoort, Nele
Christophe, Thierry
Mollat, Patrick
Lamers, Marieke
Auberval, Marielle
Hrvacic, Boska
Ralic, Jovica
Oste, Line
van der Aar, Ellen
Brys, Reginald
Heckmann, Bertrand
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (09) : 3580 - 3590

← 1 2 →